OpenAI claims AI solved three major math and physics problems, awaiting independent verification

OpenAI on Oct 26 claimed AI-generated solutions to three long-standing open problems in mathematics, computer science and physics, with a new academic-led verification model that seeks no credit for OpenAI. The claims remain unverified — math output was formalized in Lean on Oct 19 but external review is pending — and no new wet-lab validation was reported for Claude's scorpion-toxin binders or other bio candidates.

Outlook Independent verification of the three claimed proofs is likely to take weeks to months and will determine whether claims hold; early Lean formalization for the math case makes that the most testable first. No new wet-lab results for the 17 scorpion binders or other bio candidates are likely in the immediate days, so the gap between binding designs and functional validation will almost certainly persist. The shepherd model is likely to be judged by whether working groups publish transparent reviews, not by OpenAI statements alone.

The last three days added demonstrations of scale and access rather than new lab proof. OpenAI and Hugging Face showed faster, broader ways to work with biological data, while a corrective report clarified that Claude's scorpion-toxin binders are early binding designs, not a functional antivenom. No new wet-lab validation was reported for the binders or the antimicrobial peptide candidate.

Outlook In the next days, further demos of agent-scale analysis and sequence-chat tools are likely, but wet-lab validation remains the gating step. It is unlikely that binder neutralization or peptide validation results appear within days; roughly even that additional technical detail on the mouse-brain workflow and the DNA model emerges to allow independent assessment.

Three frontier labs showed parallel AI-to-bench progress in the last three days: Anthropic's Claude autonomously designed 17 validated scorpion-toxin binders, OpenAI bought Orchestra Bio to add trial-operations agents to its Rosalind life-sciences stack, and Google DeepMind demonstrated an Antigravity workflow that surfaced a new antimicrobial peptide candidate. All remain early — binding not neutralization, peptide not yet wet-lab validated, acquisition terms undisclosed — but together they mark a shift from AI as assistant to AI as autonomous designer and coordinator in biology.

Outlook Continued autonomous lab campaigns are likely in the near term as Anthropic, OpenAI and Google DeepMind compete to show bench-validated outputs, not just model benchmarks. Near-term progress will likely be measured by whether binders advance to neutralization assays and whether the Antigravity peptide validates in wet lab, rather than by additional design counts. Orchestra Bio integration is likely to focus on operational deployment inside Rosalind Workbench before any impact on trial timelines can be assessed.